TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+9.11%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.4B
AUM Growth
+$2.4B
(+12%)
Cap. Flow
+$85.1M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
48.18%
Holding
111
New
19
Increased
30
Reduced
16
Closed
10
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$35.8M |
| 2 |
AbbVie
ABBV
|
$30.2M |
| 3 |
AGN
Allergan plc
AGN
|
$25M |
| 4 |
Baxter International
BAX
|
$21.9M |
| 5 |
Gilead Sciences
GILD
|
$19.5M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$59.8M |
| 2 |
AGN
ALLERGAN INC
AGN
|
$48.5M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$28M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.8M |
Sector Composition
| 1 | Healthcare | 84.29% |
| 2 | Real Estate | 4.15% |
| 3 | Financials | 1.47% |
| 4 | Industrials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $230M | 9.11% | 1,994,834 | – | – |
|
|
2
Gilead Sciences
GILD
$140B
| $224M | 8.86% | 2,279,731 +199,000 | +10% | +$19.5M |
|
3
Biogen
BIIB
$19.4B
| $143M | 5.68% | 339,483 +12,200 | +4% | +$5.15M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $108M | 4.27% | 361,686 +84,055 | +30% | +$25M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $87M | 3.45% | 502,305 +25,200 | +5% | +$4.37M |
|
6
Incyte
INCY
$16.5B
| $85.8M | 3.4% | 936,461 | – | – |
|
7
Regeneron Pharmaceuticals
REGN
$61.5B
| $84.5M | 3.35% | 187,166 -11,200 | -6% | -$5.06M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $66.7M | 2.64% | 534,977 -35,050 | -6% | -$4.37M |
|
|
9
AbbVie
ABBV
$372B
| $65M | 2.58% | 1,110,614 +516,395 | +87% | +$30.2M |
|
|
10
Teva Pharmaceuticals
TEVA
$21.1B
| $62.2M | 2.46% | 997,594 +574,000 | +136% | +$35.8M |
|
11
Viatris
VTRS
$12.3B
| $60M | 2.38% | 1,010,105 | – | – |
|
12
Pfizer
PFE
$141B
| $57M | 2.26% | 1,638,241 | – | – |
|
13
Amgen
AMGN
$155B
| $56.2M | 2.23% | 351,779 -28,500 | -7% | -$4.56M |
|
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $54.8M | 2.17% | 464,244 -237,700 | -34% | -$28M |
|
15
Johnson & Johnson
JNJ
$427B
| $43.7M | 1.73% | 434,612 +107,400 | +33% | +$10.8M |
|
|
AKRX
16
DELISTED
Akorn, Inc.
AKRX
| $40.4M | 1.6% | 849,482 | – | – |
|
17
Alkermes
ALKS
$4.78B
| $35.9M | 1.42% | 588,470 +151,500 | +35% | +$9.24M |
|
|
AET
18
DELISTED
Aetna Inc
AET
| $35.4M | 1.4% | 331,931 | – | – |
|
19
Bristol-Myers Squibb
BMY
$96B
| $34.5M | 1.37% | 535,240 | – | – |
|
|
CTRX
20
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $25.8M | 1.02% | 433,600 | – | – |
|
21
Illumina
ILMN
$15.8B
| $24.7M | 0.98% | 133,241 +29,400 | +28% | +$5.46M |
|
22
Molina Healthcare
MOH
$9.8B
| $23.4M | 0.93% | 347,901 | – | – |
|
|
ACOR
23
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $22.7M | 0.9% | 680,862 +407,700 | +149% | +$13.6M |
|
|
ENDP
24
DELISTED
Endo International plc
ENDP
| $22.6M | 0.89% | 251,773 | – | – |
|
|
25
Baxter International
BAX
$12.7B
| $21.9M | 0.87% | +319,600 | New | +$21.9M |
|